Ichnos Glenmark Innovation Files US FDA Application for Solid Tumour Drug ISB 2301
Ichnos Glenmark Innovation (IGI), a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, has submitted an investigational new drug application to the US FDA for ISB 2301, a first-in-class pentaspecific cancer immunotherapy targeting solid tumours. The drug aims to activate T cells and natural killer cells while targeting three tumour-associated antigens to overcome tumour diversity and immune suppression. IGI plans to start Phase I clinical trials in 2027, pending regulatory approval, following promising preclinical results.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 42/100.
Outlets measured: moneycontrol, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 17 Nov, 04:08 pm. Other outlets followed.
